Perth partnership targets childhood blindness and $1 billion market, page-14

Drawing upon another comment by the CEO from the Annual Report, PYCs lead program is the 'tip of the iceberg'. There are over 6000 rare diseases of which 80% are genetic in origin. Using the CMMIT as a handbook, the Centre's molecular therapy research department, led by Professors Wilton and Fletcher, are currently looking at over 50 different diseases.

Indeed, long term funding is key once the platform is validated with the current lead program. In his post of 15/10/2019, SoT outlined a way forward using the route followed by Stoke Therapeutics. The vision is currently bigger than the funding resources available to small Australian biotechs. The urgency based upon unmet need in a myriad of debilitating conditions may make everyone strive towards global delivery.